It is the anniversary of the report of the parliamentary inquiry into approval processes for new medicines and medical technologies and still no government response, but we do have the outcome of the review of the base-case discount rate. They both say so much about the current state of policy-making in Australia. We also answer audience questions on top-down patient consultation and whether everyone should be watching what's happening with the medical device sector.

Latest Video
New Stories
-
Former Medicines NZ chair says the time for talk on Pharmac is over
December 5, 2023 - - Latest News -
Ex-TGA head John Skerritt appointed to Medicines Australia board
December 5, 2023 - - BioPharma -
FDA confirms approach to Sofdra NDA resubmission and the materials required
December 4, 2023 - - Australian Biotech -
National Pharmacies opens its first 24-7 pharmacy under South Australian initiative
December 4, 2023 - - Latest News -
PharmAust completes Phase 1 MEND study and files for US Orphan Drug Designation
December 4, 2023 - - Australian Biotech -
OncoSil Medical onboards first patient in the PANCOSIL clinical trial
December 4, 2023 - - Australian Biotech -
Korean regulator approves Amplia Therapeutics' pancreatic cancer trial
December 4, 2023 - - Australian Biotech